Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Medtronic
Mallinckrodt
Harvard Business School
Fish and Richardson
Daiichi Sankyo
Citi
Fuji
Dow

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZYRTEC-D 12 HOUR

« Back to Dashboard

Clinical Trials for Zyrtec-d 12 Hour

Trial ID Title Status Sponsor Phase Summary
NCT00240032 A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®. Completed Teva Pharmaceutical Industries Phase 4 This study is designed to compare injection skin (injection site) reactions when an antihistamine (Zyrtec®) or placebo is taken prior to performing daily Copaxone® injections. Patients will be assigned (like a flip of a coin) to take either a placebo or an antihistamine (Zyrtec®) prior to performing their daily Copaxone® injections. The patient and physician will be unaware whether they are taking a placebo or antihistamine during the study.
NCT00375713 Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema Completed UCB Pharma Phase 3 Korean double-blind non-inferiority study to asses the efficacy (as measured by the responder rate of pruritus severity score by the patient at visit 4 or end-of-treatment visit over the 2 weeks treatment period) and safety of Xyzal® to Zyrtec® in subjects suffering from dermatitis and eczema with pruritus symptoms
NCT00420082 A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber Completed Faes Farma, S.A. Phase 2 This is a randomized, double blind, active and placebo controlled, 4 way crossover study in patients with seasonal allergic rhinitis. Patients will receive a single dose of bilastine 20 mg, Cetirizine 10 mg, Fexofenadine 120 mg, and placebo in the Vienna Challenge Chamber.
NCT00504933 Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis Completed Faes Farma, S.A. Phase 3 The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of seasonal allergic rhinitis.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Zyrtec-d 12 Hour

Condition Name

Condition Name for Zyrtec-d 12 Hour
Intervention Trials
Healthy 6
Allergic Rhinitis 6
Seasonal Allergic Rhinitis 5
Perennial Allergic Rhinitis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Zyrtec-d 12 Hour
Intervention Trials
Rhinitis 13
Rhinitis, Allergic 12
Rhinitis, Allergic, Seasonal 6
Rhinitis, Allergic, Perennial 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Zyrtec-d 12 Hour

Trials by Country

Trials by Country for Zyrtec-d 12 Hour
Location Trials
United States 10
Canada 2
Austria 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Zyrtec-d 12 Hour
Location Trials
Maryland 3
Texas 3
New York 1
California 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Zyrtec-d 12 Hour

Clinical Trial Phase

Clinical Trial Phase for Zyrtec-d 12 Hour
Clinical Trial Phase Trials
Phase 4 10
Phase 3 5
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Zyrtec-d 12 Hour
Clinical Trial Phase Trials
Completed 24
Not yet recruiting 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Zyrtec-d 12 Hour

Sponsor Name

Sponsor Name for Zyrtec-d 12 Hour
Sponsor Trials
Merck Sharp & Dohme Corp. 7
Faes Farma, S.A. 3
Mylan Pharmaceuticals 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Zyrtec-d 12 Hour
Sponsor Trials
Industry 26
Other 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
McKesson
Cipla
US Department of Justice
Boehringer Ingelheim
US Army
Fuji
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.